Boyer, Inc.

Boyer, Inc. is a global biotechnology and pharmaceutical company headquartered in Cambridge, Massachusetts, renowned for its pioneering work in oncology and immunology. Founded in 1978 by Dr. Eleanor Vance, a former researcher at the Massachusetts Institute of Technology, the company has grown from a startup focused on monoclonal antibody technology into a major player in the development of targeted cancer therapies. Its research has been instrumental in advancing the field of precision medicine, leading to several FDA-approved treatments for various malignancies.

History

The company's origins trace back to the laboratory of Dr. Eleanor Vance at the Massachusetts Institute of Technology, where early work on hybridoma technology laid the groundwork. Following its incorporation in 1978, initial funding was secured from venture capital firms in Boston and the National Institutes of Health. A major breakthrough came in 1992 with the approval of its first drug, Theraceptin, for breast cancer, cementing its reputation. The early 2000s saw significant expansion through the acquisition of ImmunoGenix in 2004 and a strategic joint venture with Takeda Pharmaceutical Company in 2008. More recently, the company has invested heavily in CAR-T cell therapy platforms, partnering with institutions like the Dana-Farber Cancer Institute.

Products

The company's portfolio is dominated by innovative biologics and small-molecule drugs primarily targeting hematologic malignancies and solid tumors. Its flagship product, Theraceptin, a monoclonal antibody, remains a cornerstone of treatment for HER2-positive breast cancer. The immunotherapy drug Vaxcel, approved in 2015 for melanoma and non-small cell lung cancer, represents a major advance in checkpoint inhibitor therapy. Other key products include Lymprox for non-Hodgkin lymphoma and Kinexis, a tyrosine kinase inhibitor for renal cell carcinoma. Its pipeline includes investigational therapies for glioblastoma and pancreatic cancer, developed in collaboration with the MD Anderson Cancer Center.

Operations

The company maintains a global footprint with primary research and development facilities in Cambridge, Massachusetts, and San Francisco, alongside major manufacturing plants in Research Triangle Park and Cork, Ireland. Its clinical trial operations are extensive, conducting Phase III trials across hundreds of sites in North America, Europe, and Asia. A state-of-the-art biologics production facility in Singapore serves the Asia-Pacific market. Logistics and distribution are managed through partnerships with firms like McKesson Corporation and AmerisourceBergen, ensuring supply chain resilience. The European Medicines Agency and Japan's Pharmaceuticals and Medical Devices Agency are key regulatory partners for international approvals.

Corporate affairs

The company is led by CEO Marcus Thorne and operates under a board of directors that includes notable figures from academia and industry, such as Dr. Linda Choi of Stanford University. It has faced scrutiny from the U.S. Securities and Exchange Commission regarding disclosure practices and settled a notable patent infringement lawsuit with Roche in 2019. The company is a member of the Pharmaceutical Research and Manufacturers of America and consistently ranks highly on the Dow Jones Sustainability Index. Its philanthropic arm, the Boyer Foundation, focuses on grants for global health initiatives and STEM education programs, often in partnership with the World Health Organization.

See also

* Biotechnology industry * History of the pharmaceutical industry * Monoclonal antibody therapy * Precision medicine * List of largest pharmaceutical companies

Category:Biotechnology companies of the United States Category:Pharmaceutical companies of the United States Category:Companies based in Cambridge, Massachusetts Category:1978 establishments in Massachusetts